BioMarin Pharmaceutical Inc.
DE ˙ DB ˙ US09061G1013
46,59 € ↑0,90 (1,97%)
2026-06-04
DEL PRIS
SecurityDE:BM8 / BioMarin Pharmaceutical Inc.
InstitutionSei Investments Co
Latest Disclosed Ownership276,603 shares
Latest Disclosed Value $ 16,439,102
Sei Investments Co reports 28.51% increase in ownership of BM8 / BioMarin Pharmaceutical Inc.

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 276,603 shares of BioMarin Pharmaceutical Inc. (DE:BM8) valued at $14,034,836 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 215,237 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 28.51% during the quarter. The current value of the position is $12,886,934 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 276,603 61,366 28.51 16,439 41.05 0.0162
2025-11-13 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 215,237 133,660 163.85 11,656 160.10 0.0125
2025-08-14 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 81,577 2,011 2.53 4,481 -20.30 0.0052
2025-05-14 2025-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 79,566 8,572 12.07 5,623 20.51 0.0072
2025-05-13 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 77,294 6,300 5,172 0.0056
2025-02-11 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 70,994 -101,141 -58.76 4,666 -61.44 0.0060
2024-11-12 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 172,135 -3,296 -1.88 12,098 -16.24 0.0157
2024-08-13 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 175,431 3,321 1.93 14,443 -3.92 0.0205
2024-05-07 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 172,110 3,318 1.97 15,032 -7.64 0.0220
2024-02-14 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 168,792 86 0.05 16,275 9.04 0.0261
2023-11-14 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 168,706 -1,341 -0.79 14,927 1.27 0.0268
2023-08-11 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 170,047 -2,189 -1.27 14,740 -12.00 0.0257
2023-05-12 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 172,236 12,000 7.49 16,748 1.00 0.0311
2023-02-10 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 160,236 4,422 2.84 16,582 25.55 0.0368
2022-11-14 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 155,814 2,349 1.53 13,208 3.83 0.0295
2022-08-15 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 153,465 185 0.12 12,721 7.59 0.0275
2022-05-13 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 153,280 -4,189 -2.66 11,824 -15.03 0.0238
2022-02-14 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 157,469 -3,641 -2.26 13,916 11.78 0.0261
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 161,110 423 0.26 12,449 -7.18 0.0261
2021-08-06 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 160,687 -9,013 -5.31 13,412 4.64 0.0297
2021-05-12 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 169,700 -36,731 -17.79 12,817 -29.14 0.0323
2021-02-08 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 206,431 -5,966 -2.81 18,088 12.38 0.0468
2020-12-04 2020-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 212,397 -202,421 -48.80 16,095 -68.50 0.0466
2020-11-06 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 214,563 -200,255 16,260 39,150.4648
2020-08-17 2020-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 414,818 78,313 23.27 51,099 79.83 0.1586
2020-08-11 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 193,485 -143,020 16,580 44,974.1325
2020-05-14 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 336,505 148,059 78.57 28,415 78.37 0.1044
2020-02-06 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 188,446 37,645 24.96 15,930 56.87 0.0475
2019-11-12 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 150,801 28,023 22.82 10,155 -3.41 0.0260
2019-08-14 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 122,778 -16,117 -11.60 10,513 -14.85 0.0343
2019-05-15 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 138,895 -17,518 -11.20 12,346 -17.59 0.0415
2019-02-13 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 156,413 10,211 6.98 14,981 5.66 0.0533
2018-11-08 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 146,202 900 0.62 14,178 3.58 0.0514
2018-08-03 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 145,302 -1,224 -0.84 13,688 15.24 0.0465
2018-05-11 2018-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 146,526 -84,429 -36.56 11,878 -42.33 0.0455
2018-02-08 2017-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 230,955 -5,727 -2.42 20,595 -6.51 0.0715
2017-11-06 2017-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 236,682 -9,302 -3.78 22,029 -1.39 0.0783
2017-07-31 2017-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 245,984 62,793 34.28 22,340 38.92 0.0891
2017-05-05 2017-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 183,191 16,427 9.85 16,081 16.40 0.0705
2017-02-02 2016-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 166,764 50,421 43.34 13,815 28.34 0.0669
2016-11-04 2016-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 116,343 45,987 65.36 10,764 96.64 0.0547
2016-08-11 2016-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 70,356 -11,625 -14.18 5,474 -19.05 0.0328
2016-05-10 2016-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 81,981 -41,372 -33.54 6,762 -47.67 0.0421
2016-02-03 2015-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 123,353 98,145 389.34 12,923 386.74 0.0788
2015-11-02 2015-09-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 25,208 4,446 21.41 2,655 -6.48 0.0244
2015-10-30 2015-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 25,208 2,656
2015-08-07 2015-06-30 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 20,762 -450 -2.12 2,839 7.38 0.0257
2015-08-04 2015-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 20,762 -450 2,839 0.0257
2015-05-14 2015-03-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 21,212 -619 -2.84 2,644 34.01 0.0230
2015-05-01 2015-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 21,212 2,644
2015-02-10 2014-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 21,831 21,831 1,973 0.0174
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.